Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 22;9(1):2617.
doi: 10.1038/s41598-019-38885-0.

Heterosubtypic cross-protection correlates with cross-reactive interferon-gamma-secreting lymphocytes in the ferret model of influenza

Affiliations

Heterosubtypic cross-protection correlates with cross-reactive interferon-gamma-secreting lymphocytes in the ferret model of influenza

Karen E Gooch et al. Sci Rep. .

Abstract

An effective universal vaccine for influenza will likely need to induce virus-specific T-cells, which are the major mediator of heterosubtypic cross-protection between different subtypes of influenza A virus. In this study we characterise the cell-mediated immune response in ferrets during heterosubtypic protection induced by low-dose H1N1 virus infection against an H3N2 virus challenge, given 4 weeks later. Although the ferrets were not protected against the infection by H3N2 virus, the duration of virus shedding was shortened, and clinical disease was markedly reduced. No cross-reactive neutralizing antibodies were detected, but cross-reactive interferon-gamma-secreting T cells were detected in the circulation prior to H3N2 challenge. These T-cells peaked at 11 days post-H1N1 infection, and were strongly induced in blood and in lung following H3N2 infection. The rapid induction of interferon-gamma-secreting cells in ferrets previously infected with H1N1 virus, but not in naïve ferrets, suggests induction of memory T-cells. These results are in accord with the observations that pre-existing cross-reactive T-cells correlate with protection in humans and have implications for outbreak modelling and universal vaccine design.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Study design. Each group comprised 6 ferrets. Groups H1/H3, H1/H1 and H1/cull received identical doses of 100 pfu H1N1 virus on day 0. Groups H1/H3 and PBS/H3 received identical doses of 100 pfu H3N2 virus on day 28, whereas group H1/H1 received a second 100 pfu dose of H1N1 virus (homologous challenge). Nasal washes, heparinised blood samples and sera were collected from all animals at time-points specified in Methods. Red triangles indicate collection of PBMC and lung lymphocyte samples. i.n., intra-nasal inoculation.
Figure 2
Figure 2
Signs of clinical disease following second virus challenge. Groups H1/H3 and PBS/H3 were challenged with H3N2 virus, group H1/H1 with H1N1 virus. (a) frequency of sneezing following challenge, sum for each group; (b) AUC for temperature between 50 and 82 hours post-challenge; (c) AUC for weight between days 0 and 14 post-challenge. Weights were normalised to weight on day of challenge. In panels b and c, points represent individual ferrets and bars represent group means and standard deviations. Groups were compared by 1-way ANOVA with Holm-Sidak’s multiple comparisons test. *p < 0.05; ***p < 0.001.
Figure 3
Figure 3
Virus titres in nasal wash following second virus challenge. Points show log mean with standard deviation for each group. Time 0 samples were collected 2 days prior to challenge.
Figure 4
Figure 4
Nasal wash live cell counts. Lines show mean and standard deviation for each group. Ferrets were infected on days 0 and 28 (arrows).
Figure 5
Figure 5
Antibody response to initial infection with H1N1 virus (or PBS control). (a) geometric mean HAI titres, (b) geometric mean neutralization titres. Limit of detection in a is 4, values < 4 were scored as 2. Limit of detection in b is 10, values < 10 were scored as 5. Error bars show standard deviation. Solid bars show response to H1N1 virus, hatched bars show response to H3N2 virus. Sera were collected 24 days post-infection.
Figure 6
Figure 6
ELISpot titres in PBMC. (a) stimulation with H1N1 virus, (b) stimulation with H3N2 virus. Points show individual ferrets, with mean and standard deviation overlaid. Groups were compared by Kruskall-Wallis test, using Dunn’s multiple comparisons test. *p < 0.05. The values marked with a circle in group PBS/H3 are from the same ferret.
Figure 7
Figure 7
ELISpot titres in lung MNC. (a) stimulation with H1N1 virus, (b) stimulation with H3N2 virus. Points show individual ferrets, with mean and standard deviation overlaid. Groups were compared by Kruskall-Wallis test, using Dunn’s multiple comparisons test. *p < 0.05, **p < 0.01. The values marked with a circle in group PBS/H3 are from the same ferret as highlighted in Fig. 6.
Figure 8
Figure 8
Whole blood IFN-γ ELISA. Bars show group mean values in pg/ml following stimulation with (a) H1N1 virus and (b) H3N2 virus. Arrows indicate the timing of the first and second infections, at days 0 and 28. Error bars show standard error of the mean. Upper limit of detection was 12000 pg/ml.

References

    1. World Health Organization Influenza (seasonal) fact sheet. http://www.who.int/mediacentre/factsheets/fs211/en/ Accessed 14-feb-18 (2018).
    1. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine. 2007;25:6852–6862. doi: 10.1016/j.vaccine.2007.07.027. - DOI - PubMed
    1. Hillaire ML, Rimmelzwaan GF, Kreijtz JH. Clearance of influenza virus infections by T cells: risk of collateral damage? Current opinion in virology. 2013;3:430–437. doi: 10.1016/j.coviro.2013.05.002. - DOI - PubMed
    1. Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scandinavian journal of immunology. 2004;59:1–15. - PubMed
    1. Grant EJ, Quinones-Parra SM, Clemens EB, Kedzierska K. Human influenza viruses and CD8(+) T cell responses. Current opinion in virology. 2016;16:132–142. doi: 10.1016/j.coviro.2016.01.016. - DOI - PubMed

Publication types

MeSH terms

Substances